Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Omthera Pharmaceuticals

- PMLiVE

NICE backs expanded use of Brilique in final guidance

AZ’s maintenance therapy recommended for long-term use, post-heart attack

AstraZeneca AZ

AstraZeneca shaken by FDA partial hold on durvalumab trial

Aims to resume trial recruitment as soon as possible after bleeding side effects curb study

- PMLiVE

Pharma Perspectives: The agency selection process (part 2)

AstraZeneca's Samuel Hollis on the evolution of the agency selection process

- PMLiVE

Rigel shaken after fostamatinib misses phase III trial target

Firm will still pursue early 2017 FDA approval for the autoimmune disease therapy

- PMLiVE

Synairgen sinks as AZ halts trial of asthma drug

Results from a phase II trial of inhaled antiviral therapy set to be inconclusive

- PMLiVE

Tesaro’s niraparib threatens Lynparza after acing ovarian cancer trial

Maintenance therapy significantly improved progression-free survival regardless of BRCA status

- PMLiVE

Call for better patient-focused information in cancer

PatientView survey highlights shortcomings in explaining newer science

National Institute for Health and Care Excellence NICE logo

AstraZeneca’s Forxiga set to be recommended by NICE

The type 2 diabetes ‘triple therapy’ is backed in draft guidance

- PMLiVE

Another failed trial knocks back AZ’s plan to grow Brilinta

Rests hopes on ongoing diabetes study but looks set to fall short of $3.5bn annual target

- PMLiVE

Reformed Cancer Drugs Fund backs its first drug – AZ’s Tagrisso

Lung cancer treatment will be available to NHS patients while NICE awaits data

AstraZeneca AZ

AZ licenses inflammatory bowel disease drug to Allergan for $1.52bn

Will receive $250m upfront with a further $1.27bn if drug reaches market in two indications

- PMLiVE

Transformational technology

Big data, the cloud and the value of insights

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links